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5’-Peptide oligonucleotide conjugates were prepared stepwise on a single support using 
Nα-Fmoc- protected amino acids and unprotected phosphate groups. The method uses 
commercially available reagents and is successful with most natural amino acids. The 
simplicity of the method may encourage researchers to prepare new oligonucleotide-
peptide conjugates with novel properties. 
 
The use of synthetic oligonucleotides to control gene expression has triggered the 
search for new oligonucleotide derivatives to improve their therapeutic potential.1 
Oligonucleotide-peptide conjugates are chimeric molecules consisting of 
oligonucleotides covalently linked to peptides. As a result, synthetic oligonucleotides 
acquire some of the biological and/or biophysical properties of peptides. Thus, linking 
peptides to oligonucleotides may have beneficial effects such as: (a) facilitating 
oligonucleotide transport through cell membranes2, (b) increased stability to 
exonucleases3, (c) improved binding to complementary sequences4, and (d) greater rate 
of hybridization5.  
Two strategies can be followed to synthesize oligonucleotide-peptide conjugates.4 In the 
post-synthetic conjugation approach, the two moieties are prepared independently and 
specific groups (such as thiols and maleimido) are specifically incorporated to link both 
molecules.6 In the stepwise approach, oligonucleotide-peptide conjugates are prepared 
by stepwise addition of amino acids and nucleobases in solid phase on the same solid 
support.7 In this case, the problem is the incompatibility of the standard schemes of 
protection for peptides and oligonucleotides. For example, at the end of the solid-phase 
peptide synthesis, a treatment with acid is usually required, which can provoke partial 
depurination of DNA. In the synthesis of oligonucleotide 3'-peptides, this problem could 
be averted by using Nα-tert-butoxycarbonyl (Boc)-protected amino acids with base 
labile groups for the protection of side chains, a base-labile linker and standard 
phosphoramidites,7a-e or by using Nα-9-fluorenylmethoxycarbonyl (Fmoc)-protected 
amino acids.7f-h But these methods could not be applied for the incorporation of peptides 
at the 5’ end or in the middle of the oligonucleotide sequence, as required for some 
applications such as gene delivery.8  
Recently, a method for the solid-phase synthesis of oligonucleotide-5’-peptide 
conjugates has been described.9 It is based on the use of a protecting group [2-
(biphenyl-4-yl)propan-2-yloxycarbonyl, Bpoc] for the α-amino group of the amino 
acids that can be removed in mild acid conditions suitable for DNA. Similarly, the 
monomethoxytrityl (MMT) group has been used for the synthesis of DNA/PNA 
chimeras.10 
In this paper we describe the use of common Fmoc-amino acids for the stepwise 
synthesis of oligonucleotide-5’-peptide conjugates. Although the Fmoc-removal 
conditions are not orthogonal to the base-labile cyanoethyl protection of the DNA 
phosphotriester moieties, we found that the presence of unprotected phosphate groups 
did not hinder the assembly of small peptide sequences on oligonucleotide supports. 
NPPLPPGPC is a proline-rich peptide that has recently been prepared in our laboratory 
for NMR structural studies using standard Fmoc chemistry. We chose this as a model to 
test the methodology because it does not contain trifunctional amino acids. The self-
complementary octanucleotide sequence (5’CCAATTGG3’) was prepared on controlled 
pore glass (CPG), polystyrene (LV200) and polystyrene-polyethylenglycol (PS-PEG) 
supports using standard 2-cyanoethyl phosphoramidite protocols. After the assembly of 
the oligonucleotide sequence, an amino group was added to the 5’-end using the N-6-
MMT-aminohexyl phosphoramidite (Scheme 1). Aliquots of the 5’-amino support 
carrying the 5’amino oligonucleotide were placed in a syringe and the tripeptide PGP 
was assembled using standard Fmoc-chemistry (Scheme 1). It was also assembled using 
Nα-trityl-protected amino acids.11 Unfortunately, during the latter assembly reactivity of 
the carboxyl functions was poor due to steric hindrance of the trityl group and severe 
truncation by acetylation was observed. Acetylation (from capping reagents) together 
with isobutyrylation and benzoylation of the peptide sequence was described by 
Zaramella et al.9 as one of more severe side reactions occurring during the assembly of 
peptide at the 5’-end of the oligonucleotides. Surprisingly, the peptide sequence 
assembled using Nα-Fmoc-protected amino acids showed only mild truncation by 
acetylation at the 5’-aminooligonucleotide site even after repetitive capping with acetic 
anhydride after each amino acid addition (see Figure S1). We believe that the piperidine 
treatment applied during the removal of the Fmoc group eliminates the “reactive” acetyl 
groups in the support and the assembly of the peptide sequences is thus more efficient. 
We also found that polystyrene (LV200) and CPG supports gave good results, the 
former being slightly better. Unfortunately, the oligonucleotide-peptide conjugate could 
not be obtained on the PS-PEG support. 
 
Scheme 1. Solid-phase synthesis of 5’-peptide oligonucleotide conjugates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Next we prepared the heptapeptide sequence as well as related tri- and tetrapeptide 
sequences with trifunctional amino acids on CPG supports carrying 5’-amino 
oligonucleotides (see Table 1). Whenever possible, protecting groups labile to mild 
acidic conditions (such as 1% trifluoroacetic acid) were used to protect side chains of 
Nα-Fmoc-protected amino acids. 
Amino acids with a carboxylic acid side-chain (Asp, Glu) were protected as 2-
phenylisopropyl (PhiPr) esters. First, the hexanucleotide NPD(PhiPr)PC-5’CAATTG3’ 
was assembled. The support was then treated with 3% trichloroacetic acid (TCA) in 
CH2Cl2 for 10 min to remove the PhiPr group, and then with ammonia. The desired 
oligonucleotide-peptide conjugate was present as the major component of the crude. 
Unfortunately, ammonia removed the PhiPr group if TCA treatment was omitted. It was 
important ensure that the PhiPr group was completely removed by the TCA treatment 
since hydrolysis by ammonia may lead to the corresponding amide instead of carboxylic 
acid. The amide peptide is difficult to detect. Using a model peptide (PheGluPro-amide) 
prepared on polystyrene we demonstrate that the PhiPr group is completely removed by 
3% TCA giving glutamic acid (see supporting information). Therefore, after ammonia 
deprotection the desired oligonucleotide-peptide conjugates carrying glutamic acid are 
obtained. 
Unprotected Fmoc-Asn and Fmoc-Gln can be used for the synthesis of peptides, 
although these amino acids are frequently protected with the trityl (Trt) group. We 
attempted to use both unprotected and Trt-protected glutamine (entries 6 and 9, Table 1) 
but we observed that the trityl group of glutamine was not removed by 3% TCA (entry 
6, Table 1). Stronger acidic conditions will be needed to remove the Trt group which are 
not appropriate for DNA. In contrast, the desired tetrapeptide (entry 9, Table 1) was 
obtained using unprotected Fmoc-glutamine. 
Two side-chain derivatives of lysine were tested successfully. The derivative of lysine 
carrying the trifluoroacetyl (Tfa) group is already used for the synthesis of 
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oligonucleotide-3’-peptide conjugates because it is removed in ammonia.7 Sequence  
NPKPC-5’CCAATTGG3’ (entry 4, Table 1) was obtained in good yields using Fmoc-
Lys(Tfa)-OH. Furthermore, the derivative of lysine carrying the acid labile MMT group 
was appropriate for the preparation of  the oligonucleotide carrying the tetrapeptide 
NPKEPC-5’CCAATTGG3’ (entry 9, Table 1). This result was expected because the 
MMT group also protects the 6-aminohexyl moiety. The nuclear localization signal 
(NLS) peptide AKKKKLDP was also prepared using Fmoc-Lys(Tfa)-OH and Fmoc- 
Asp(PhiPr)-OH (entry 14, Table 1). 
Next, four derivatives of histidine were tested. The Trt derivative described previously 
for the preparation of oligonucleotide-3’peptide conjugates12 was too stable because, 
like Trt in Gln, it was not removed by 3% TCA (entry 7, Table 1). In contrast, the Boc-
protected derivative was removed by 3% TCA (entry 10, Table 1). The base labile Fmoc 
and the tosyl derivatives were also suitable for the preparation of conjugates carrying 
histidine (entries 11, 13 Table 1). 
Amino acids carrying alcohol groups were protected with Trt (Thr) and chlorotrityl 
(ClTrt) (Tyr) groups. Both were removed by 3% TCA (entries 8 and 9, Table 1). 
 
 
 
 
Table 1. Characterization of oligonucleotide 5’-peptide sequences. 
No. oligonucleotide-peptide 
sequence 
side-chain 
protecting 
groupa 
HPLC 
(min)b 
mass (MALDI) 
found / calcd 
Tm 
(ºC)c 
1 NPDPC-5’CAATTG3’ D(PhiPr) 9.0 2278.3/ 2278.4 -- 
2 NPGPC-5’CCAATTGG3’ -- 10.4 2838.8/ 2839.7 37.1 
3 NPPLPPGPC-
5’CCAATTGG3’ 
-- 11.8 3243.3/ 3244.2 36.5 
4 NPKPC-5’CCAATTGG3’ K(Tfa) 10.7 2908.2/ 2910.8 38.6 
5 NPKEPC-5’CCAATTGG3’ K(MMT) 
E(PhiPr) 
9.9 3036.5/ 3038.9 40.0 
6 NPQ(Trt)PC-5’CCAATTGG3’ Q(Trt) 21.7 3150.3/ 2910.8d 39.6 
7 NPH(Trt)PC-5’CCAATTGG3’ H(Trt) 21.6 3160.5/ 2919.8d 40.2 
8 NPMTPC-5’CCAATTGG3’ T(Trt) 12.2 3013.1/ 3014.9 37.7 
9 NPYQPC-5’CCAATTGG3’ Y(ClTrt) 11.8 3073.3/ 3074.0 44.1 
10 NPHPC-5’CCAATTGG3’ H(Boc) 10.6 2918.3/ 2919.8 39.0 
11 NPHPC-5’CCAATTGG3’ H(Fmoc) 10.7 2917.8/ 2919.8 40.0 
12 NPWPC-5’CCAATTGG3’ -- 13.9 2967.5/ 2968.9 43.9 
13 NPHCPC-5’CCAATTGG3’ H(Tos) 
C(MMT) 
11.6 3020.6/ 3022.8 40.1 
14 NAKKKKLDPC-
5’CCAATTGG3’ 
K(Tfa) 
D(PhiPr) 
10.2 3495.2/ 3495 38.5 
15 5’CCAATTGG3’ -- 8.8 -- 36.5 
 
aAbbreviations: PhiPr: 2-phenylisopropyl ester, Trt: trityl, Tfa: trifluoroacetyl, MMT: 
monomethoxytrityl, Boc: t-butyloxycarbonyl, Tos: Tosyl, Fmoc: 9-
fluorenyloxycarbonyl, ClTrt: 2-chlorotrityl. bRetention time (min) in HPLC (see 
Supporting Information). c1M NaCl, 0.1M sodium phosphate pH 7.0. dMass calculated 
for the trityl-protected derivative. 
 
 
Fmoc-Trp and Fmoc-Met were successfully used without protection (entries 8 and 12,  
Table 1). It is important to notice that Met needs protection as sulfone when the peptide 
is assembled before the oligonucleotide, because it is unstable during the phosphite-to-
phosphate oxidation.13 In our case the peptide is assembled after the oligonucleotide, so 
there is no need to protect Met because there is no oxidation step. Unprotected Fmoc-
arginine was also tested using carbodiimide activation with an excess of 1-
hydroxybenzotriazole to keep the guanidine group of arginine in the protonated form.7d 
However, peptide elongation did not occur in these conditions. Carbodiimide activation 
is inefficient within CPG supports.7g Although we did not test it, arginine may be 
obtained by introduction of the guanidine group in ornithine.14 Cysteine was protected 
by the acid labile MMT group (entry 13, Table 1). This conjugate was highly sensitive 
to ammonia and it was obtained in low yields (see below). 
During the synthesis of the PGP-octanucleotide conjugate we used the standard 
ammonia deprotection conditions (55 ºC, overnight). These conditions were also used 
for the remaining sequences because the amide linkage between peptide and 
oligonucleotide is stable to ammonia. But when trifunctional amino acids such as 
histidine or cysteine were present in the peptide sequence the oligonucleotide part 
underwent sever hydrolysis, as described elsewhere.7 This problem was averted by 
reducing the time of the ammonia treatment (1 h, at 55 ºC) or lowering the temperature 
(overnight, at room temperature).  
Finally, some authors have recommended the use of the sarcosyl linkage between 
oligonucleotide and solid support to avoid premature removal of the oligonucleotide 
during the piperidine treatment to eliminate the Fmoc groups. In order to assess the 
extent of this side reaction, we treated oligonucleotide supports with the piperidine 
solution, followed by analysis of the filtrates. We conclude that this side reaction is 
negligible in the synthesis of small peptides on oligonucleotide-supports (see supporting 
information).  
Melting temperatures of self-complementary oligonucleotide-peptide conjugates are 
shown in Table 1. Melting curves were obtained in high salt conditions in order to be 
able to measure melting temperatures. In agreement with previous reports15 the presence 
of the peptide induced a small duplex-stabilizing effect, especially when tryptophan and 
tyrosine residues are present. Coulombic charge screening by high salt eliminates the 
beneficial effect of cationic side chains. For this reason peptides carrying Lys and His 
do not stabilize duplex structure in the conditions used in this work. On the contrary, 
high salt may push aromatic amino acids (Trp, Tyr) into the minor groove, thus 
stabilizing the duplex. 
In summary, we have developed an efficient and general method for the synthesis of 
short oligonucleotide-5’-peptide conjugates using commercially available products such 
as standard DNA synthesis reagents, amino modifiers and Fmoc-protected amino acids. 
The method allows the preparation of the oligonucleotide-peptide conjugates in any 
laboratory without the need to prepare special reagents. We believe that this method 
may have a strong impact on a large number of laboratories by opening the possibility 
of finding more and more applications for molecules of this type.  
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Experimental Section. 
 
Synthesis of oligonucleotide-peptide conjugates.  
Oligonucleotides were prepared on an automatic Applied Biosystems 392 DNA 
synthesizer on several batches of 1 μmol scale (CPG) or 0.2 μmol scale (polystyrene, 
LV200) using commercially available reagents (Applied Biosystems, USA) following 
standard protocols. The phosphoramidite of MMT-6-aminohexanol derivative 
(Cruachem, Scotland and Glen Research, USA) was used for the incorporation of an 
amino group at the 5’-end of the sequence. During the addition of the amino linker we 
avoided the use of the capping step to prevent partial acetylation of the amino group. 
The MMT group was removed using 3% TCA in DCM and the resulting support was 
stored in the refrigerator in the protonated form.  
Solid-phase peptide synthesis were performed manually in a batch procedure using Nα-
Fmoc-protected  amino acids (Bachem, Germany and Novabiochem, Switzerland). 
Syntheses were performed on 0.2-0.5 μmol scale. The following synthesis protocol was 
applied for all conjugates. First, the support was neutralized with 5% DIPEA in DCM 
and washed in CH3CN. The resulting support was treated with a mixture of Fmoc-
amino acid (20 equiv), PyBOP (20 equiv) and DIPEA (40 equiv) in 0.2-0.3 ml of DMF 
for 30 min. Then, the solution was filtered and the support was washed in DMF and 
CH3CN.  
The Fmoc group was then removed using a 20% piperidine solution in DMF for 5 min 
and the support was washed in CH3CN.  At the end of the synthesis if acid-labile 
groups were used for the protection of the side chains of the amino acid, the support 
was treated with a 3% TCA solution in DCM for 10 min and washed in CH3CN. After 
the assembly of the sequences, supports were treated with 32% aqueous ammonia at 55 
ºC for 16 h. In some cases, when trifunctional amino acids (such as histidine, cysteine) 
were present the oligonucleotide moiety underwent sever hydrolysis, which was 
strongly reduced by treating the supports with 32% aqueous ammonia at 55 ºC for 1 h 
or at room temperature overnight. 
Ammonia solutions were concentrated to dryness and the products were desalted over a 
Sephadex G-25 (NAP-25) column eluted with water. Yields 7-15 O.D. units at 260 nm. 
The resulting products were further purified by reversed-phase HPLC. Solutions were 
as follows. Solvent A: 5% CH3CN in 100 mM TEAA pH 6.5 and solvent B: 70% 
CH3CN in 100 mM TEAA pH 6.5. Columns: PRP-1 (Hamilton), 250 x 10 mm. Flow 
rate: 3 ml/min. A 20 min linear gradient from 0-50% B and 5 min isocratic at 50% B. 
Yields 2-6 O.D. units at 260 nm, except for the conjugate PHCP-octamer that was 0.6 
O.D. units. The HPLC retention time, mass spectrometry and melting temperature data 
are shown in Table 1. 
 
Carboxylic acid versus carboxamide during ammonia deprotection of 2-
phenylisopropyl esters. 
In order to check whether the PhiPr group was completely removed with the TCA 
treatment we used a model tripeptide (PheGluPro, FEP). First FEP-amide and FQP-
amide were prepared using standard Fmoc-chemistry on polystyrene (Rink amide resin, 
Novabiochem, Switzerland). FEP-amide, MS (MALDI-TOF): Calcd. 391.4; found 
413.23 (M+ Na) and 429.21 (M+K), HPLC (see conditions above) 10.0 min; FQP-
amide, MS (MALDI-TOF): Calcd. 390.4; found 413.22 (M+ Na) and 429.18 (M+K), 
HPLC (see conditions above) 8.25 min.  
Next, two aliquots of PheGlu(PhiPr)Pro-support were treated: (I) with concentrated 
ammonia (55 ºC overnight) and (II) first with 3% TCA for 10 min followed by 
concentrated ammonia (55 ºC overnight). Afterwards, the resulting supports were 
collected and treated with 95%TFA/ 5% water to remove the peptide from the support. 
HPLC analysis (see conditions above) of the resulting products indicated that the  direct 
treatment of PheGlu(PhiPr)Pro-support with ammonia produced a mixture of two 
tripeptides: 15% of the tripeptide with glutamine and 85% of the peptide with glutamic 
acid. The same tripeptide-support treated with ammonia after a 10 min treatment with 
3% TCA in DCM yielded the tripeptide carrying glutamic acid as single compound 
(>95%). This indicates that the PhiPr group was completely removed by 3% TCA 
solution followed by ammonia yielding the desired oligonucleotide-peptide conjugates. 
 
Stability of succinyl linkage to piperidine. 
A 5 mg aliquot of DMT-5’CCAATTGG3’-succinyl-CPG support was treated with 20% 
piperidine/ DMF for 1 h at room temperature. The filtrate was concentrated to dryness 
and the resulting residue was first dissolved in water and then analysed by UV-
spectroscopy at 260 nm. The aqueous solution was concentrated to dryness and 1 ml of 
perchloric acid/ ethanol (3:2) was added. The absorption of the solution at 500 nm was 
measured. Next, the support obtained after the piperidine treatment was treated with 3% 
TCA/ DCM and the coloured DMT cation solution was collected and dried, and 1 ml of 
perchloric acid/ ethanol (3:2) was added to the resulting residue. The remaining support 
was treated with concentrated ammonia (1 h, 55 ºC) and filtered. The filtrates were 
analysed by UV-spectroscopy at 260 nm. Comparison of the DMT cation and DNA 
absorbance between filtrates and support after piperidine treatment gave a loss of 5-10% 
of DMT-oligonucleotide after one hour of treatment. This result is consistent with a 
study of the stability of oligonucleotides linked to solid supports to bases (Aviñó, A., 
Güimil García, R., Díaz, A., Albericio, F., Eritja, R. Nucleosides Nucleotides 1996, 15, 
1871-1889) and shows that premature removal oligonucleotide from succinyl supports 
during piperidine treatments needed for the removal of the Fmoc groups (5 min per 
cycle) is about 0.4-0.8% per cycle. We conclude that this side reaction is negligible in 
the synthesis of small peptides on oligonucleotide-supports.  
 
Melting experiments. Melting experiments were performed as follows. Solutions of the 
appropriate oligonucleotide-peptide conjugates (approx. 0.5 O.D. units) were prepared 
in a solution containing 1M NaCl, 100mM sodium phosphate buffer of pH 7.0. The 
solutions were heated to 90 ºC, allowed to cool slowly to room temperature and stored 
at 4 ºC until UV measurement. UV absorption spectra and melting experiments 
(absorbance vs temperature) were recorded in 1 cm path-length cells using a 
spectrophotometer, with a temperature controller and a programmed temperature 
increase rate of 0.5 ºC/min. Melting curves were recorded at 260 nm and melting 
temperatures were measured at the maximum of the first derivatives of the melting 
curves. 
 
 
Figure S1: HPLC trace of crude NPro-Gly-ProC-5’CCAATTGG3’ prepared on 
polystyrene supports (LV200) using capping after the addition of each amino acid (see 
conditions in experimental section). The major peak at 10.3 min shows the expected 
molecular weight for the desired oligonucleotide-peptide conjugate. Other side products 
observed in the mass spectra of the crude are octanucleotide (failure on the addition of 
the 5’ amino modifier) and 5’ acetyl-amino-octanucleotide (acetylation of 5’-amino 
oligonucleotide) 
 
 
 
 
Figure S2: HPLC trace of crude NPro-His-ProC-5’CCAATTGG3’ prepared on 
controlled-pore glass (CPG) using the tert-butoxycarbonyl group (Boc) for the 
protection of histidine (see conditions in experimental section). Ammonia treatment 
was performed at 55 ºC for 1 h. The major peak at 10.6 min shows  the expected 
molecular weight for the desired oligonucleotide-peptide conjugate.  
 
 
 
  
 
 
 
 
 
 
 
 
 
